03/13/2020 /
The Phase 2b StATES study of Staccato® alprazolam met its primary endpoint which was proportion of responders achieving cessation of seizure activity within two minutes of treatment administration and no recurrence within two hours.
03/11/2020 /
The Bordey lab reports the elevated expression of actin-cross linking protein filamin A in the brain tissue of many patients with two genetic disorders linked to intractable seizures: tuberous sclerosis complex and a subset of focal cortical dysplasia type II.
03/06/2020 /
Clearer guidance will enhance clinicians’ confidence in communicating person centered epilepsy risk with people with epilepsy and their families thus improving outcomes.
03/06/2020 /
According to the researchers, this study reveals signs of inflammation, neuronal damage and transitory disruption of blood brain barrier following single generalized convulsive seizures.
03/06/2020 /
Check out the latest updates from CURE CEO, Beth Lewin Dean.
03/04/2020 /
The Marigold Study is a pivotal Phase 3 study evaluating oral ganaxolone in children and young adults with CDKL5 Deficiency Disorder (CDD).
03/04/2020 /
The majority of TBI-, epilepsy-, and PTE-related online health education materials do not meet the sixth grade reading recommendation.
03/04/2020 /
This review aims to provide information to neurologists and epileptologists on the therapeutic value of CBD products, principally a purified form, in routine practice for patients with intractable epilepsy.
03/04/2020 /
The agency now expects to provide a decision by June 25 on whether to approve Fintepla for the treatment of seizures associated with Dravet.
